We appreciate the comments of Drs Zittermann and Wallis and their colleagues with regard to vitamin D. The Women's Health Initiative Calcium/Vitamin D trial was designed in the early 1990s to assess whether calcium/vitamin D supplementation reduced hip fracture 1 ; cardiovascular events were secondary, albeit prespecified, outcomes. The trial chose the vitamin D 3 supplement dose of 200 IU twice daily because it was the recommended daily allowance at that time, had low risk of toxicity, raised 25-hydroxy vitamin D 3 concentrations to acceptable levels, 2 and slowed bone loss. 3 In 1999, the Institute of Medicine confirmed 400 IU daily as an adequate intake of vitamin D for healthy older women to maintain bone health and normal calcium metabolism. 4 In our trial, vitamin D intake (supplements and diet) at baseline was Ϸ365 IU daily; women randomized to active supplements thus consumed Ϸ765 IU daily, well above the recommended adequate intake, and a dose sufficient to favorably affect hip bone mineral density. 5 Although calcitriol was not measured, baseline serum 25-hydroxy vitamin D levels (Liaison chemiluminescent immunoassay; DiaSorin Inc., Stillwater, Minn.) were Ͻ30 ng/mL in 87% of a subsample of hip fracture cases (nϭ1818) and 85% of matched controls (nϭ1813). Thus, a higher dose of vitamin D supplementation may well be needed to achieve optimal effects on bone metabolism and to demonstrate any potential impact on cardiovascular events.
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Nonetheless, we have demonstrated that supplementation with currently recommended quantities of vitamin D does not modulate risk of coronary events or stroke. The safety of higher doses of supplements would need to be evaluated, bearing in mind the increased incidence of kidney stones in our trial among women assigned to active calcium/vitamin D supplements (449 versus 381 among women assigned to placebo; hazard ratio, 1.17; 95% confidence interval, 1.02 to 1.34). 5 
